Member Info for SGD27

... which is referring to this :

https://eplanning.blm.gov/epl-front-office/eplanning/planAndProjectSite.do?methodName=renderDefaultPlanOrProjectSite&projectId=1505504&dctmId=0b0003e8814fe9ed

https://www.sunriseresourcesplc.com/downloads/sunrise-resources-plc-rns-cs-project-release-of-environmental-assessment-15-may-2020.pdf

@Craiggy : Not sure it warrants an RNS just yet, but perhaps when the public consultation dates get filled in.

https://eplanning.blm.gov/epl-front-office/eplanning/planAndProjectSite.do?methodName=renderDefaultPlanOrProjectSite&projectId=1505504&dctmId=0b0003e8814fe9ed

Hi Terrafin & fulmar29, I did gradually sell off my MARL/SSL holding - I wouldn't have if I'd foreseen Covid-19! Might get back in if PoG & SSL SP drop significantly (unlikely I think). Was always a little nervous about Turkey - less so about Nevada!

Hi Dubliner, it's probably obvious that I'm in camp 1.

The permit delay is certainly frustrating. One minor consolation is that the Covid-19 impact might have been much worse if
we were half way through a mine build, with contractors involved and so on. As things stand I hope we can somehow just hibernate through it.

Interesting new research study (in vitro), which may be relevant :

https://www.uc.edu/news/articles/2020/05/n20914652.html

"The researchers hope to learn how interferons activated in COVID-19 infections defend the heart and whether the SARS-CoV-2 spike protein binding to a specific receptor causes cardiomyocyte injury, says Sadayappan. They will also test the heart-specific protective effects of several medications being studied in the treatment of COVID-19 patients."

Pharmaxis have had a minor setback which means that a $10m payment they were expecting in Q4 2020 has moved back to Q1 2021. I wonder if this will increase the urgency of getting the LOXL2 partnering done?

http://www.pharmaxis.com.au/assets/Documents/pdf/02020/ASX/2020-05-13-Bronchitol-FDA-Goal-Date.pdf

The latest from Canadian interferon enthusiast, Dr Eleanor Fish :

https://www.theglobeandmail.com/canada/article-interferon-emerges-as-potential-treatment-for-covid-19/

@Crookie36340 : But did you see my post 18:26 yesterday?!

This is interesting. The old EU document

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB

says

"E.8.7 Trial has a data monitoring committee No"

whereas the new US document

https://clinicaltrials.gov/ct2/show/record/NCT04385095?term=synairgen

says

"Has Data Monitoring Committee Yes"

Here's a follow-on review regarding the Hong Kong trial :

https://emcrit.org/pulmcrit/combination/

The author, Josh Farkas, seems to rate it a lot higher than the recent remdesivir results.

@Woodstock1970 : According to RM on LBC radio, it's the results from the first part of the trial (hospital-based) that are expected at the end of June.

Tuesday, 5 May, approx 57 minutes in:

https://www.globalplayer.com/catchup/lbc/uk/b8FPfUZ/

@notnow20, he also said this later on :

"So, the next step, of course, is to see whether this regimen works in severe cases, if we have more severe cases in the coming winter, or that is that we will be looking at whether we can actually use interferon in patients who presented beyond seven days, which we think that this is not a, you know…a lot of the pro-inflammatory adverse effect is not a problem anymore. We can actually give interferon for patient who present beyond seven days. So, we’ll be looking at that, as well."

Podcast relating to the Hong Kong trial :

https://podcasts.jwatch.org/index.php/podcast-266-interferon-and-early-treatment-in-covid-19-bring-good-outcomes/2020/05/10/

This is interesting :

"Prof. Ian Hung, the lead author on the report, explains that the researchers were afraid of prompting a cytokine “storm” if interferon was given after 6 days of symptoms — they’re not sure that that reluctance was well founded now."

Thanks Borsaci06, great research!

@PJ Thanks for replying.

"The global Unexpanded Perlite Market was valued at USD 8 million in 2016 and is projected to touch USD 11 million by 2024."

OK, but you didn't include the word "Unexpanded" in your original post, you just said

"The Perlite industry is only set to hit 11million by 2024. What do you think Sunrise Resources share would be of that?"

You aren't thinking that the "Unexpanded Perlite Market" includes the perlite that gets expanded and then enters the Expanded Perlite Market are you?

(The Expanded Perlite Market is estimated at US$678 million in 2020. Source :
https://www.themarketreports.com/report/global-expanded-perlite-market-research-report
)

SNG was included in that system on 6th April

http://www.aktiencheck.de/news/Artikel-FRA_New_Instruments_available_on_XETRA_06_04_2020_002-11159631

@ShareSting "JBER has been controlling the price for the last 3 weeks"

Do you think they are the link through to the Frankfurt exchange XETRA system, which we were discussing about a month ago?

https://www.boerse-frankfurt.de/equity/synairgen-plc-ls-01

Since the delay is being debated again, I'll repeat my speculation from late last night.

I'm wondering if they paused recruitment while they got the faster turnaround virus test in place, so that it could be applied to as many subjects as possible.

I'm referring to the amendment dated 22/04/2020 here :

https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/281317/